Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning

Citation for published version (APA):
Heckman, P. R. A., van Duinen, M. A., Bollen, E. P. P., Nishi, A., Wennogle, L. P., Blokland, A., & Prickaerts, J. (2016). Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications. *International Journal of Neuropsychopharmacology, 19*(10), [pyw030]. https://doi.org/10.1093/ijnp/pyw030

Document status and date:
Published: 01/10/2016

DOI:
10.1093/ijnp/pyw030

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 18 Aug. 2023
REVIEW

Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications

Pim R. A. Heckman, MSc; Marlies A. van Duinen, PhD; Eva P. P. Bollen, PhD; Akinori Nishi, PhD; Lawrence P. Wennogle, PhD; Arjan Blokland, PhD; Jos Prickaerts, PhD

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (Mr Heckman, Dr van Duinen, Dr Bollen, and Dr Prickaerts), and Department of Neuropsychology and Psychopharmacology (Mr Heckman and Dr Blokland), Maastricht University, Maastricht, The Netherlands; Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, Japan (Dr Nishi); Intra-Cellular Therapies, Inc., New York, New York (Dr Wennogle).

Correspondence: Jos Prickaerts, PhD, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, 6200 MD Maastricht, The Netherlands (jos.prickaerts@maastrichtuniversity.nl).

Abstract

Background: The fronto-striatal circuits are the common neurobiological basis for neuropsychiatric disorders, including schizophrenia, Parkinson's disease, Huntington's disease, attention deficit hyperactivity disorder, obsessive-compulsive disorder, and Tourette's syndrome. Fronto-striatal circuits consist of motor circuits, associative circuits, and limbic circuits. All circuits share 2 common features. First, all fronto-striatal circuits consist of hyper direct, direct, and indirect pathways. Second, all fronto-striatal circuits are modulated by dopamine. Intracellularly, the effect of dopamine is largely mediated through the cyclic adenosine monophosphate/protein kinase A signaling cascade with an additional role for the cyclic guanosine monophosphate/protein kinase G pathway, both of which can be regulated by phosphodiesterases. Phosphodiesterases are thus a potential target for pharmacological intervention in neuropsychiatric disorders related to dopaminergic regulation of fronto-striatal circuits.

Methods: Clinical studies of the effects of different phosphodiesterase inhibitors on cognition, affect, and motor function in relation to the fronto-striatal circuits are reviewed.

Results: Several selective phosphodiesterase inhibitors have positive effects on cognition, affect, and motor function in relation to the fronto-striatal circuits.

Conclusion: Increased understanding of the subcellular localization and unraveling of the signalosome concept of phosphodiesterases including its function and dysfunction in the fronto-striatal circuits will contribute to the design of new specific inhibitors and enhance the potential of phosphodiesterase inhibitors as therapeutics in fronto-striatal circuits.

Keywords: fronto-striatal circuits, dopamine, phosphodiesterase, phosphodiesterase inhibitors, cyclic adenosine monophosphate
Introduction

Several neuropsychiatric disorders, including Parkinson’s disease, Huntington’s disease, attention-deficit hyperactivity disorder (ADHD), Tourette’s syndrome, schizophrenia, and obsessive-compulsive disorder, share the fronto-striatal circuits, also known as cortico-striatal-thalamic circuits, as their neurobiological basis. The fronto-striatal circuits comprise motor, cognitive, and limbic circuits (Alexander et al., 1986, 1990; Alexander and Crutcher, 1990). These circuits operate in a very complex manner that is extensively described elsewhere (Surmeier et al., 2007; Haber and Rauch, 2010; Gerfen and Surmeier, 2011; Surmeier et al., 2011; Calabresi et al., 2014). Dysfunction of these circuits produces the wide range of motor, cognitive, and affective symptoms observed in related neuropsychiatric disorders. One prominent feature of the complex functioning of the fronto-striatal circuits is their modulation by dopamine, both at the level of the frontal cortex as well as the striatum. As a result, dopaminergic receptors are strongly expressed throughout all fronto-striatal circuits (Gerfen and Surmeier, 2011; Nishi et al., 2011; Kuroiwa et al., 2012). Unsurprisingly, dopaminergic medication has been the first-line therapy for several disorders related to dysfunctional fronto-striatal circuits; however, efficacy is often moderate at best and accompanied by severe side effects (e.g., ADHD, schizophrenia, and Parkinson’s disease).

Dopamine originating from substantia nigra pars compacta (SNc) and/or ventral tegmental area (VTA) (nigrostriatal and mesolimbic pathways) binds to both dopamine type1 (D1) receptors and dopamine type2 (D2) receptors on medium spiny neurons (MSNs) in the striatum (Gerfen and Surmeier, 2011). D1 receptors are mainly found on MSNs of the direct pathway, and D2 receptors are mainly found on MSNs of the indirect pathway where they establish antagonistic interactions with adenosine A2A receptors (Gerfen et al., 1990; Ferre et al., 2011). Additionally, dopamine released from VTA (mesocortical pathway) also binds to D1 receptors in the frontal cortex (Kuroiwa et al., 2012). D1 receptors activate the Gαs family of G proteins to stimulate cyclic adenosine monophosphate (cAMP) production and thereby striatonigral and frontal signaling (Sibley et al., 1993; Beaulieu and Gainetdinov, 2011). In contrast, the D2 receptors couple to the Gαi/o family of G proteins and thus induce inhibition of cAMP production, thereby inhibiting striatopallidal signaling that eventually leads to disinhibition of the frontal cortex (Figure 1). Actions of the dopamine receptors in both pathways can be viewed as synergistically or complementary.

Intracellularly, the effect of dopamine on striatonigral, striatopallidal, and frontal neurons is largely mediated through the cAMP-activated cascade (Nishi et al., 2008, 2011; Nishi and Snyder, 2010; Kuroiwa et al., 2012). cAMP is synthesized from adenosine triphosphate by adenylyl cyclase, which is activated directly by activated G-protein coupled receptors or by calmodulin (CaM)-dependent protein kinase (PK)/ after Ca2+ influx. cAMP affects synaptic plasticity through both presynaptic neurotransmitter release and postsynaptic intracellular pathways (Figure 1). The former might be mediated via a presynaptic calcium (Ca2+)/CaM-dependent PK/cAMP/cAMP-dependent PKA cascade and elevation of cAMP has been found to result in the synthesis and/or release of several neurotransmitters, including 2 main players in the fronto-striatal circuits: glutamate and dopamine (Schoffelmeer et al., 1985; Imanishi et al., 1997; Rodriguez-Moreno and Sihra, 2013).

The influence on postsynaptic intracellular pathways occurs through activation of postsynaptic PKA by cAMP produced by adenylyl cyclase stimulated by either glutamatergic-induced Ca2+ influx or dopamine signaling-stimulated Gs. PKA exerts several effects related to neuroplasticity and neuroprotection. The fastest postsynaptic response in relation to neuroplasticity mediated by cyclic nucleotides is the activation and insertion of stored receptors by PKA through phosphorylation of GluR1 subunits promoting α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking into the postsynaptic membrane for potentiation of glutamatergic transmission (Song et al., 2013). In addition to the mobilization and membrane insertion of stored receptors, the process of protein synthesis (e.g., AMPA receptors) further increases neuroplasticity (Carew and Sutton, 2001; Izquierdo et al., 2006).

PKA also phosphorylates cAMP response element-binding protein (CREB) (Mayr and Montminy, 2001) and Dopamine- and cAMP-Regulated Phosphoprotein MR 32kDa (DARPP-32) (Greengard, 2001; Svenningsson et al., 2004). Phosphorylated CREB is also involved in neuroplasticity (e.g., synthesis of other proteins) (Impey et al., 1996; Lu et al., 1999; Sakamoto et al., 2011) and neuroprotection (e.g., neuronal arborization, synaptogenesis, and neurogenesis) (Mantamadiotis et al., 2002; Bruel-Jungerman et al., 2006; Sakamoto et al., 2011). One of the genes transcribed by phosphorylated CREB is bdnf (Scott Bitner, 2012). After release, the protein BDNF binds to the tropomyosin-related kinase B receptor, which is the receptor with the highest affinity for BDNF BDNF is involved in the proliferation, survival, and differentiation of new neurons (i.e., neurogenesis in the brain) (Minichiello, 2009).

In addition, the activity-dependent release of BDNF and subsequent tropomyosin-related kinase B-mediated activation of CREB is also an important mechanism of enhancing neuronal communication, specifically in active neurons of the brain. For instance, BDNF increases synaptic strength with adjacent neurons by processes like long-term potentiation (LTP), thus ameliorating their connectivity (Lu et al., 2008; Minichiello, 2009). Interestingly, LTP itself has been linked to both synaptogenesis and neurogenesis (Bruel-Jungerman et al., 2006).

DARPP-32 is phosphorylated at Thr24 in both striatal and frontal neurons. DARPP-32 thereby converts into a potent inhibitor of protein phosphatase-1 (PP-1). DARPP-32 is also phosphorylated at Thr75 by CaMK and this converts DARPP-32 into an inhibitor of PKA. Thus, DARPP-32 has the unique property of being a dual-function protein, acting either as an inhibitor of PP-1 or of Pka influencing neuroplasticity (Svenningsson et al., 2004). The inhibition of PP-1 controls the phosphorylation state and activity of many downstream physiological effectors, including various neurotransmitter receptors (e.g., AMPA receptor GluR1 subunit, N-methyl-D-aspartate receptor NR1 subunit), ion channels and pumps (e.g., N/P-type Ca2+ channels, Na+ channel, Na+, K+-ATPase), and transcription factors (e.g., CREB, c-Fos, ΔFosB) (Greengard et al., 1999). Striatal LTP and long-term depression are dependent on cAMP and DARPP-32 phosphorylation (Calabresi et al., 2000).

The cAMP/PKA cascade is thus a potential target for pharmacological intervention in neuropsychiatric disorders related to dopaminergic frontal and striatal dysfunction. cAMP is degraded by cAMP-specific phosphodiesterases (PDEs) and dual substrate PDEs. Eleven PDE families have been described, distinguished by molecular properties, substrate specificity, and regulation (Bender and Beavo, 2006). These enzymes are expressed in unique and overlapping patterns throughout the body and central nervous system (Lakics et al., 2010; Table 1). Selective PDE inhibitors (PDE-Is) prevent the degradation of cyclic nucleotides leading to increased concentrations of cAMP. Due to the differential expression of PDE subtypes in one or more of the frontal and striatal pathways or dopaminergic terminals, different subtype-specific PDE-Is enable stimulation of dopamine synthesis, inhibition of D2 receptor signaling or stimulation of D1 receptor...
Figure 1. Fronto-striatal circuits originate in the frontal cortex and pass through the basal ganglia, which project via the thalamus back to frontal brain areas. Output neurons in the striatum are medium spiny neurons (MSNs), which consist of direct pathway and indirect pathway neurons. The direct pathway neurons inhibit tonically active neurons in globus pallidus interna (GPi)/substantia nigra pars reticulata (SNr). The indirect pathway neurons activate neurons in GPi/SNr via inhibition of the globus pallidus externa (GPe) and activation of the subthalamic nucleus (STN). Direct and indirect pathway neurons induce opposing effects on the output neurons in GPi/SNr, resulting in disinhibition and proinhibition of output, respectively. Within the basal ganglia all projections are GABAergic except those from the STN. Main phosphodiesterases (PDEs) expressed in fronto-striatal circuits are PDE1B, PDE4, and PDE10A. PDE1B is generally colocalized with dopamine (DA) D1 receptors in the brain and thought to represent a major inactivation mechanism of D1 receptors. By acting like a DA D1 agonist PDE1B-Is can enhance phosphorylation of cAMP response element binding protein (CREB) as well as Dopamine- and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32) enhancing synaptic transmission (e.g., AMPA receptors), neuron excitability, and synaptic and neurogenesis, resulting in neuroplasticity and neuroprotective effects at glutamatergic frontal and fronto-striatal synapses. Regarding fronto-striatal signaling, the effect of PDE4 inhibition on cAMP/protein kinase A (PKA) signaling, is linked to indirect pathway adenosine A2a receptor signaling and has no major role in D1 receptor direct pathway signaling. An opposite situation is observed at frontal dopaminergic signaling. In the frontal cortex, PDE4 is localized at DARPP-32 expressing neurons. In contrast to the striatum, PDE4 inhibition enhances DA D1 receptor-induced phosphorylation of DARPP-32 in the frontal cortex, indicating a prominent role of PDE4 in frontal DA receptor signaling. Finally, DA release from DAergic midbrain terminals can be influenced with a PDE4 inhibitor as DA is expressed at DAergic terminals in neurons of the SNc in which cAMP has been reported to be a strong inducer of tyrosine hydroxylase (TH) gene transcription rate and mRNA affecting DA synthesis and release. In direct pathway neurons, PDE10A inhibition activates cAMP/PKA signaling related to D1 receptor signaling, whereas in indirect pathway neurons PDE10A inhibition activates cAMP/PKA signaling by simultaneous potentiation of adenosine A2A receptor signaling and inhibition of D2 receptor signaling. Effects of PDE10A inhibition are suggested to predominate the indirect pathway. In contrast to PDE4 inhibition, PDE10A inhibition does not increase TH phosphorylation and therefore has no effects on DA synthesis and release. Nevertheless, it cannot be ruled out that selective PDE inhibitors (PDE-Is) might influence both the direct and indirect pathway via enhancing the release of DA from frontal DAergic projections depending on the -to be determined- presence of PDEs in these terminals.

In striatal interneurons containing nitric oxide synthase (NOS), nitric oxide (NO) is produced and diffuses into dendrites of MSNs which contain high levels of guanylate cyclase (GC), which, when activated, lead to the synthesis of cyclic guanosine monophosphate (cGMP). In the striatum, transient elevations in intracellular cGMP, next to cAMP, primarily act to increase neuronal excitability and to facilitate glutamatergic fronto-striatal transmission. Thus, inhibition of selective PDE subtypes can also target the cGMP/protein kinase G (PKG) pathway and have an effect on fronto-striatal functioning.
signaling (Nishi et al., 2011). However, the level of expression of different PDE family members in these fronto-striatal circuits in both physiological and pathological conditions is incompletely understood and a subject of intense investigation. In the fronto-striatal circuits, the main therapeutic mechanism of PDE inhibition is enhanced neuroplasticity and neuroprotection through previously discussed CREB and DARPP-32 signaling cascades (Figure 1). However, known effects of PDE-Is on neuroinflammation and cytokine-mediated responses may play additional roles (Hebb and Robertson, 2008; Wilson and Brandon, 2015).

The integration of individual PDEs into specific signalosomes within different functional compartments has revealed the functional roles of these PDEs and linked the large number of PDE isoforms to the compartmentalized regulation of specific cyclic nucleotide signaling pathways and biological responses. This compartmentalization therefore contributes to both the fine-tuning and specificity of cyclic nucleotide signaling (Jurevicius and Fischmeister, 1996; Zaccolo et al., 2000; Mongillo et al., 2006; Maurice, 2011; Stangherlin et al., 2011; Stangerlin and Zaccolo, 2012). More in detail, compartmentalization provides spatially distinct pools of PKA and PKG to be activated in different ways. This idea was confirmed by the observation of cAMP in localized pools (Houslay, 1995). These pools are created by physical interactions between different components of signaling cascades and structural elements of the cell. Localization and activation of both cyclases and PDEs are important determinants in the process of cyclic nucleotide homeostasis by modulating fluctuations in the compartments. For PDEs, sequestration and anchoring is the principal mechanism to create cyclic nucleotide gradients (Houslay and Milligan, 1997; Houslay and Adams, 2003). Subsequently, different PDE isoforms are anchored at specific intracellular sites by A-kinase anchoring proteins (AKAPs) (Rubin, 1994). AKAPs control the gradients of cAMP in the cell and modify localized target proteins, thereby causing sequestration of PKA into distinct cellular compartments. This also applies to the fronto-striatal circuits and is considered the main determinant of the target PDE isoform within a specific neuropsychiatric disorder. In addition, different PDE isoforms can integrate multiple distinct cellular inputs and allow crosstalk between cyclic nucleotides and other signaling networks and systems (Dodge-Kafka et al., 2005; Mongillo et al., 2006; Houslay et al., 2007; Stangherlin et al., 2011; Wilson et al., 2011; Kritzer et al., 2012).

Since the focus of this review is on frontal and striatal dopaminergic regulation, PDE1B, PDE2A, PDE4, PDE7B, PDE9A, and PDE10A in particular are of special interest (Lakics et al., 2010). PDE1B, PDE7B, and PDE10A are highly enriched in striatum and/or frontal cortex. PDE2A, PDE4 (A, B, D), and PDE9A are more widely distributed but are also expressed in striatum and/or frontal cortex. There are only very limited preclinical data on PDE2A, PDE7A, and PDE9A inhibition (e.g., Duinen et al., 2015). To date, most research has been devoted to the potential of PDE1B, PDE4, and PDE10A for regulation of dopaminergic frontal and striatal signaling, and therefore these subtypes will be discussed below.

**PDE1**

**PDE1 and Dopamine Signaling**

PDE1 hydrolyzes both cAMP and cGMP. PDE1, unlike any other class of PDE, is uniquely activated by the binding of a complex of Ca<sup>2+</sup> and CaM. PDE1 is encoded by 3 separate genes: PDE1A, PDE1B, and PDE1C. PDE1B is highly colocalized with D1 receptors in the brain and is particularly rich in the striatum, hippocampus, and prefrontal cortex (Lakics et al., 2010). PDE1 activity was first described as cytosolic; however, it now appears that PDE1A is not restricted to the cytosol but is also present in the nucleus where it contributes to the regulation of transcription factors (Nagel et al., 2006). This opens a new field of research in transcriptional regulation. Changes in PDE1 location associated with cell differentiation might contribute to compartmental signaling (Nagel et al., 2006).
Implications and Clinical Overview of PDE1B-Is

PDE1B is generally colocalized with dopamine D1 receptors in the brain and thought to represent a major inactivation mechanism of D1 receptors. PDE1B is not membrane bound but contained mainly in a soluble intracellular compartment (Fusco and Giampa, 2015). Targeting this subfamily of PDEs is therefore considered a promising therapeutic strategy in disorders characterized by frontal cognitive dysfunction, like schizophrenia and ADHD. Negative and cognitive symptoms of schizophrenia are associated with reduced dopamine (D1) function in the prefrontal cortex, also referred to as hypofrontality (Li et al., 2016; Arnsten, 2013). The reduced prefrontal dopamine function disturbs the balance of excitatory to inhibitory synaptic interactions in this area (Winterer, 2006). Thus, the decreased ratio of D1/D2 signaling in schizophrenia would favor unstable cortical representation of internal and external stimuli (Winterer and Weinberger, 2004) and as such, affect cognition. Likewise, dopaminergic hypofrontality is observed in ADHD patients (Pliszka, 2005; Sagvolden et al., 2005; Arnsten and Pliszka, 2011) and linked to inattentiveness, hyperactivity, and impulsivity. By acting supposedly like a dopamine D1 agonist, a PDE1B-I can enhance phosphorylation of GluR1 subunits to potentiate glutamatergic frontal-striatal signaling. In addition, potentiation of dopamine receptors will increase phosphorylation of DARPP-32 and CREB, subsequently inducing gene expression in the prefrontal cortex and benefiting clinical symptoms by activation of neuroplasticity at prefrontal synapses.

Regarding striatal disorders like movement disorders and positive symptoms in schizophrenia, not much data is available. Assuming effects of PDE1B are indeed preferentially induced in the dopamine D1 direct pathway, subsequent DARPP-32 and CREB phosphorylation will enhance synaptic transmission, neuron excitability, and synapto-neurogenesis inducing neuroplasticity and neuroprotection at glutamatergic fronto-striatal synapses. In theory, neuropsychiatric disorders related to striatal hypofunction (like hypokinetism movement disorders such as Huntington’s disease) would benefit from stimulated plasticity in striatonigral neurons (Nishino et al., 1993; Heckman et al., 2015). This is in contrast to the desired mechanism of action of treatment for hyperkinetic movement disorders (like Huntington’s disease) and antipsychotic treatment, as both preferably target the D2 receptor striatopallidal pathway (Strange, 1998; Walker, 2007). Support for this hypothesis comes from studies that found impaired cyclic nucleotide signaling mechanisms to occur in human Parkinson’s disease as well as in experimental animals (Belmaker et al., 1978; Volier et al., 1986; Nishino et al., 1993; Sancesario et al., 2004). Additional upregulation in PDE1B activity has also been observed following 6-hydroxydopamine (6-OHDA) lesions (as a Parkinson’s model) in rats (Sancesario et al., 2004). The opposite has been observed in Huntington’s disease (Luthi-Carter et al., 2000; Nuñofora et al., 2001). These studies found decreased cyclic nucleotide (cAMP) levels in the deafferented striatum accompanied by decreased PDE1B activity. The decreased PDE1B activity may be compensatory to the decrease in cyclic nucleotide levels. CREB-mediated transcriptional dysregulation has also been reported to occur during Parkinson’s disease pathology. PDE1-Is have been tested in an animal model of haloperidol-induced catalepsy. As haloperidol is a potent D2 dopamine receptor antagonist, interference with D2 dopamine receptors causes significant motor disturbances seen frequently with schizophrenics treated with antipsychotic medicines. The haloperidol-induced catalepsy model is capable of testing agents for exacerbation or lessening of these motoric effects. The potent and selective PDE1-I, ITI-214 (see below), reversed the haloperidol-induced catalepsy, indicating the potential use of this mechanism to reverse such motoric effects (Wennogle et al., 2010).

BDNF has been demonstrated to exert protective actions on nigral dopaminergic neurons in vivo and in vitro models of Parkinson’s disease (Hyman et al., 1991; Levivier et al., 1995; Shults et al., 1995; Hung and Lee, 1996; Feng et al., 1999; Mohapel et al., 2005; Sun et al., 2005), whereas inhibition of nigral BDNF expression has been reported to cause dopaminergic neuronal loss (Porritt et al., 2005). Postmortem studies have demonstrated reduced levels of BDNF within the SNc in Parkinson’s disease patients (Mogi et al., 1999; Parain et al., 1999; Howells et al., 2000; Chauhan et al., 2001). Furthermore, during in vitro experiments, BDNF has been demonstrated to promote the survival and differentiation of mesencephalic dopaminergic neurons (Hyman et al., 1991; Feng et al., 1999). The enhancement of cerebral cyclic nucleotide levels by PDE1B inhibition would improve CREB-mediated signaling mechanisms providing therapeutic effects in Parkinson’s disease.

Recently, a set of 4 clinical studies were performed with a truly selective and potent PDE1-I, ITI-214 (Li et al., 2016a). With the exception of work performed with vinpocetine, a nonselective agent as noted above, ITI-214 is the first selective PDE1-I studied in humans. Clinical evaluations included a series of Phase I single- and multiple ascending-dose studies performed in the US and Japan. ITI-214 was given orally to healthy volunteers and patients using once-a-day dosing and was shown to be safe and well tolerated, with a linear pharmacokinetic profile. This study has been reported in a press release (Intra-Cellular Therapies, 2014), where the company concludes that “these studies represent a significant milestone as the first demonstration of the safety of a potent and highly specific PDE1-I in humans.”

PDE4

PDE4 and Dopamine Signaling

PDE4, which is cAMP specific, is encoded by 4 distinct genes in mammals, PDE4A, PDE4B, PDE4C, and PDE4D, and is expressed as at least 25 splice variants. Each of these variants has a modular structure consisting of a variant-specific N-terminal domain,
regulatory domains (upstream conserved region 1 and 2 [UCR1 and UCR2]), a conserved catalytic domain, and an isoform-specific C-terminal domain (McCaughill et al., 2008; Gurney et al., 2011; Richter et al., 2015). Transcription of a number of PDE4 genes is activated by the cAMP/PKA/CREB cascade (D’Sa et al., 2002; Le Jeune et al., 2002), and PKA induction of PDE4 genes serves as a long-term feedback mechanism. The N-terminal domain and UCR1/2 interact with variant-specific binding proteins to direct the subcellular targeting of PDE4 variants (McCaughill et al., 2008).

Various targeting proteins have been identified, including arrestin, AKAPs, receptor for activated C kinase 1, disrupted in schizophrenia 1, Src, and extracellular receptor kinase (ERK) (see Nishi and Snyder, 2010).

Nishi and colleagues (2008) showed that the inhibition of PDE4 by rolipram weakly enhanced cAMP/PKA signaling both in neostriatal slices and in vivo (Nishi et al., 2008). Rolipram increased the phosphorylation of DARPP-32 but only at high concentrations. Rolipram treatment enhanced adenosine A1 receptor-mediated phosphorylation of DARPP-32 but had no effect on D1 receptor/cAMP/PKA-mediated phosphorylation at the level of DARPP-32. Enhanced adenosine A1 receptor-mediated signaling is expected to oppose actions of the dopamine D2 receptor in striatopallidal neurons. These findings may suggest that PDE4 is exclusively expressed in indirect pathway neurons. However, immunohistochemical analysis of previously mentioned neostriatal slices revealed that PDE4 expression can be found in both pathways but with a higher expression in indirect pathway neurons. Regarding striatal dopaminergic signaling, it seems that the effect of PDE4 inhibition on cAMP/PKA signaling is linked to adenosine A1 receptor signaling and has no major role in striatal dopamine signaling. An opposite situation is observed at frontal dopaminergic signaling. In the frontal cortex, several PDE isoforms are expressed in cortical neurons (Cherry and Davis, 1999; Pérez-Torres et al., 2000). For the mouse frontal cortex, it has been described that PDE4B is localized at DARPP-32-expressing neurons (Nishi and Snyder, 2010). In contrast to the striatum, rolipram enhanced dopamine D1 receptor-induced phosphorylation of DARPP-32 in the frontal cortex, indicating a prominent role of PDE4 in frontal dopamine receptor signaling. Finally, dopamine is known to be expressed at dopaminergic terminals in neurons of the SNc (Cherry and Davis, 1999), where cAMP has been reported to be a strong inducer of tyrosine hydroxylase (TH) gene transcription rate and mRNA affecting dopamine synthesis (Kumer and Vrana, 1996; Chen et al., 2008). Rolipram enhanced haloperidol-induced phosphorylation of TH at Ser40 in presynaptic dopamine terminals with a proportional increase in dopamine synthesis though failed to do so in the absence of haloperidol. Also, rolipram enhanced levels of 3,4-Dihydroxyphenylacetic acid and the 3,4-Dihydroxyphenylacetic acid/dopamine ratio, indicating an increased dopamine metabolism. However, no increase in the level of dopamine itself was found, indicating the absence of a direct effect on dopamine release (Nishi et al., 2008).

Implications and Clinical Overview of PDE4-Is

Compared with PDE1, much more is known regarding the role of PDE4 in frontal and striatal dopaminergic functioning. However, by no means have all the effects been unraveled and all the questions been resolved for PDE4. PDE4 inhibition has been shown to increase dopaminergic tone in striatal neurons by increasing both synthesis and metabolism, though lacking a direct effect on release. It is known that basal ganglia functioning depends on specific amounts of dopamine in order to function at peak performance. Low levels of dopamine cause movement difficulties, while excessive dopamine causes involuntary movements. Even if PDE4 inhibition itself may not be involved in the process of releasing dopamine, the enhanced production of the dopamine precursor levodopa by enhanced cAMP-stimulated TH gene transcription may result in enhanced stimulus-driven dopamine release. PDE4-Is may therefore constitute an interesting treatment for neuropsychiatric disorders involving hypo-functioning striatal dopamine systems, like Parkinson’s disease. Indeed, rolipram has been reported to attenuate MPTP-induced dopamine depletion in the striatum and reduce the loss of nigral TH-positive neurons in vitro (Hulley et al., 1995a; Yamashita et al., 1997a, 1997b) and in vivo (Hulley et al., 1995b; Yang et al., 2008). Next, it remains to be seen if these effects on synthesis and metabolism also apply to frontal dopaminergic terminals arriving from the VTA. If so, PDE4 would be an interesting target for disorders characterized by frontal dopaminergic dysfunction, like ADHD or schizophrenia (cognitive and negative symptoms). Frontal dopaminergic hypofunctioning can not only be opposed by PDE4 inhibition via augmented release of neurotransmitters at dopaminergic terminals but also, like previously discussed for PDE1B, by means of increased DA D1 receptor/cAMP/PKA signaling inducing DARPP-32 and CREB phosphorylation, leading to concomitant gene transcription related to neuronal plasticity. Because PDE4 inhibition affects both these mechanisms, PDE4-Is are particularly interesting as a potential treatment for ADHD and schizophrenia. Finally, in the striatum, PDE4 inhibition regulates adenosine A1 signaling and is therefore often viewed as exerting dopamine D2 antagonistic effects, although it may also be viewed as mimicking the effect of an adenosine A1 agonist. Both would indicate antipsychotic potential of PDE4-Is by counteracting hyperdopaminergia, which has been confirmed by several studies over the years, including early clinical trials (Casacchia et al., 1983; Parkes et al., 1984; Siciak, 2008). Based on results of rolipram, this latter mechanism is also applicable to Huntington’s disease. Rolipram exerted neuroprotective effects in 2 rodent Huntington’s disease models via increased CREB phosphorylation and subsequent targets like BDNF (DeMarch et al., 2007, 2008; Fusco and Giampa, 2015). Neuroprotective effects of rolipram were induced by sparing of striatal neurons, prevention of intranuclear inclusion formation, and attenuation of microglial reactivity (DeMarch et al., 2008). Furthermore, rolipram was effective in preventing CREB binding protein sequestration into striatal neuronal intranuclear inclusions, sparing interneurons of R6/2 mice and rescuing motor coordination and activity deficits (Giampa et al., 2009b; but see Hannan, 2009). However, there are a range of molecular and cellular mechanisms implicated in the pathogenesis of Huntington’s disease (Gil and Rego, 2008).

When examining actual clinical data, the first clinical trials into PDE4 were done in the field of depression research (Esposito et al., 2009). These first clinical studies showed a good antidepressant response to rolipram treatment (Zeller et al., 1984; Fleischhacker et al., 1992). However, rolipram produces severe dose-limiting side effects, including emesis, headache, gastric hyper secretion, nausea, and vomiting. This has put a serious hold on the further development of rolipram and other related PDE4-Is. It also prevented rolipram from reaching the market. Yet, a clinical Phase II trial started in 2006 to reevaluate the antidepressant properties of rolipram (estimated study completion date: December 2013). No details are yet available to the scientific community. Another PDE4-1, ND1251, was reported to improve memory in a group of 8 depressed subjects (Outsourcing Pharma, 2014).

Although rolipram was primarily developed for treating depression (Zeller et al., 1984; Fleischhacker et al., 1992),
rolipram has also been investigated in early clinical trials as a treatment for Parkinson’s disease (Casaccia et al., 1983; Parkes et al., 1984). Some positive effects of rolipram were observed, however not exceeding the efficacy of levodopa or other dopaminergic drugs. At the moment, second-generation PDE4-Is are being developed, which are supposed to have less-emetnic side effects and are being studied for other disorders besides depression. As a result, roflumilast was approved by the Food and Drug Administration (FDA) in 2011 as an antiinflammatory drug for the treatment of Chronic Obstructive Pulmonary Disease exacerbations. PDE4-Is were also tested in clinical trials as treatment for schizophrenia. Takeda has recently finished a proof of mechanism Phase I clinical study with the PDE4-I roflumilast in combination with second-generation antipsychotics in schizophrenia patients (ClinicalTrials.gov Identifier: NCT02079844).

PDE4-Is were also examined as a treatment for Huntington’s disease. The new experimental PDE4-I GSK356278 was tested by GlaxoSmithKline as a new treatment for Huntington’s disease in 2 subsequent Phase I studies. In 2012, the first Phase I study was completed investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK356278 (ClinicalTrials.gov Identifier: NCT01573819). GSK356278 was well tolerated when it was given as a single dose to healthy people, and in this study the objective was to observe effects of GSK356278 after daily intake. Subsequently, a second Phase I positron emission tomography brain occupancy study of GSK356278 was conducted in male healthy volunteers (ClinicalTrials.gov Identifier: NCT01602900; no results are disclosed). It is currently unclear whether this PDE4-I treatment is aimed at the motor or cognitive symptoms observed in Huntington’s disease.

Of note, ibudilast (or AV-411) is another PDE4-I in development as an antiinflammatory drug to treat, for instance, Amyotrophic Lateral Sclerosis (ClinicalTrials.gov Identifier: NCT02238626). However, this compound not only inhibits PDE4 but also serves as a glial activator. Central nervous system applications of AV-411 are being explored in clinical Phase II studies, that is, pain and drug abuse (ClinicalTrials.gov Identifier: NCT00723177, NCT01217970, NCT02025998, NCT01868087). Additionally, different genetic studies have shown a positive relationship between PDE4B polymorphisms and schizophrenia, which likely results in significantly decreased PDE4B levels as detected in postmortem brain tissue (Fatemi et al., 2008a; Guan et al., 2012). Low PDE4B levels, which might be considered as a compensatory mechanism, do not necessarily result in increased cAMP levels, as several mechanisms can also be activated that counteract the decreased degradation of cAMP by PDE4B. Another genetic link is related to the gene Disrupted-in-Schizophrenia-1 (DISC1; Harrison and Weinberger, 2005). A chromosomal translocation of this gene increases susceptibility for schizophrenia (Millar et al., 2000; Sachs et al., 2005), and, interestingly, binding of DISC1 to PDE4B is disrupted, which might result in an overactivity of the latter (Millar et al., 2005; Murdoch et al., 2007).

PDE10

PDE10 and Dopamine Signaling

PDE10, which is encoded by PDE10A, is a dual substrate PDE, hydrolyzing both cAMP and cGMP. PDE10A is present both in striatogniral direct and striatopallidal indirect pathway MSNs (Xie et al., 2006; Nishi et al., 2008). Additionally, PDE10A regulates cAMP/PKA signaling (Nishi et al., 2008) and gene expression (Strick et al., 2010) in the MSNs of both pathways. Interestingly, PDE10A hydrolyzes both cAMP and cGMP, but it has an approximate 20-fold higher affinity for cAMP (Bender and Beavo, 2006), making it an interesting target for disorders involving the fronto-striatal circuits. In the striatum, PDE10A is expressed in both direct and indirect pathway MSNs, but not in interneurons (Menniti et al., 2007; Megens et al., 2008; Sano et al., 2008). Of the 3 splice variants, PDE10A2 is associated with the membrane, whereas PDE10A1 and PDE10A3 are found in the cytosol (Kotera et al., 2004). In the striatum, mainly PDE10A2 is expressed, and it is found at membranes in dendrites and spines of MSNs (Xie et al., 2006). PDE10A2 is phosphorylated by PKA at Thr16 within the N-terminal region (Kotera et al., 2004). Nishi and colleagues argue that this seems to induce the translocation of PDE10A2 from membrane to cytosol, thereby controlling cAMP/PKA signaling within the spines (Nishi and Snyder, 2010; see also Wilson and Brandon, 2015).

Through this effect on cAMP/PKA signaling, PDE10A inhibition by papaverine showed enhanced phosphorylation of CREB and ERK (Rodefer et al., 2005; Siucjak et al., 2006; Becker and Grecksch, 2008) and of their downstream targets DARPP-32 and GluR1 (Nishi et al., 2008) at PKA sites in striatal MSNs both in vitro and in vivo. More specifically, in both direct and indirect pathway neurons, PDE10A shows equal expression patterns (Xie et al., 2006; Nishi et al., 2008; Sano et al., 2008), regulation of cAMP/PKA signaling (Nishi et al., 2008), and gene expression (Strick et al., 2010). However, distinguishing between both pathways, in direct pathway neurons, PDE10A inhibition activates cAMP/PKA signaling related to D1 receptor signaling (Nishi et al., 2008), whereas in indirect pathway neurons, PDE10A inhibition activates cAMP/PKA signaling by simultaneous potentiation of adenosine A_a receptor signaling and inhibition of D2 receptor signaling. A study of neuronal type-specific regulation of DARPP-32 phosphorylation at Thr34 using neostriatal slices showed that papaverine increased DARPP-32 phosphorylation by 6-fold in indirect pathway neurons, whereas it increased DARPP-32 phosphorylation by only 2-fold in direct pathway neurons, indicating that effects of PDE10A inhibition predominate the indirect pathway (Rateup et al., 2008; Nishi et al., 2008). Recent electrophysiological results support this conclusion (Threlfall et al., 2009). More support is provided by recent behavioral studies published by different groups; however, these latter studies also show substantial D1 direct pathway effects of PDE10A-Is (Megens et al., 2014a, 2014b; Gentzel et al., 2015; Suzuki et al., 2016).

In vivo, PDE10A-Is are studied mostly for effects on spontaneous or stimulated behaviors providing evidence for predominant indirect pathway effects (similar to effects of D2 receptor blockers). This would include inhibition of spontaneous or stimulant-induced behavior, inhibition of conditioned avoidance behavior, reversal of stimulant-induced sensory gating deficits, and preferential activity against apomorphine-induced climbing (Schmidt et al., 2008; Grauer et al., 2009; Kehler and Nielsen, 2011; Gresack et al., 2013; Megens et al., 2014b). However, concomitant D1 receptor stimulation causes reduced efficiency against behavioral stimulants via direct pathway activation (Menniti et al., 2007; Sotty et al., 2009; Gresack et al., 2013; Megens et al., 2014b). D1 receptor stimulation is also responsible for the cognition-enhancing effects (Rodefer et al., 2005; Grauer et al., 2009) and socializing effects (Grauer et al., 2009) of PDE10A-Is. So indeed, there is compelling evidence for substantial direct pathway activation of PDE10A-Is. This latter notion is supported by recent work from Megens and coworkers (2014a) in suppressed behavior via D1 receptor blockade, D2 receptor blockade or dopamine depletion. Their results indicate
that PDE10A-Is reverse behavioral suppression after D1 receptor blockade (hypolocomotion) via direct pathway activation (next to suppressing stimulant behavior via indirect pathway activation). These effects are indicative of substantial D1 agonistic effects of PDE10A-Is (next to their D2 antagonistic effects). Still, the main effects of PDE10A-Is are suggested to be exerted through the indirect pathway. By this route, PDE10A-Is can cause extrapyramidal side effects, resembling D2 receptor blockers. The latter may explain why PDE10A-Is have not yet reached the market as antipsychotic treatment. This notion is supported by the recent failure of the Pfizer PDE10A-1 MP-10 (or PF-02545920) in a Phase II clinical trial as antipsychotic treatment, where it showed no efficacy on positive and negative symptoms and produced motor side effects (akathisia and dystonia) in patients with schizophrenia (DeMartinis et al., 2012).

Finally, in contrast to PDE4 inhibition by rolipram, PDE10A inhibition by papaverine showed no increases on TH phosphorylation at Ser40 (PKA site), suggesting no effects of PDE10A inhibitors on dopamine synthesis. Of note, only at high concentrations did papaverine show an effect on TH phosphorylation. Also, results for papaverine should be confirmed by using the more potent PDE10A-Is TP-10 and MP-10. Additionally, PDE10A inhibition showed no effects on dopamine metabolism (Nishi et al., 2008). Therefore, in contrast to PDE4, it is assumed that PDE10A does not play a major role at dopaminergic terminals.

Implications and Clinical Overview of PDE10A-Is

PDE10A is even more extensively studied in relation to the fronto-striatal circuits than the previously discussed PDE4 and PDE18 subtypes. Due to the hypothesis of a higher expression in indirect pathway neurons, PDE10A-Is have received much attention as potential dopamine D2 antagonists and as such for their antipsychotic properties. Historically, positive symptoms in schizophrenia have been linked to overstimulation of dopamine receptors in the striatum (Baumeister and Francis, 2002), which is attenuated by PDE10A inhibition-induced dopamine D2 receptor antagonism. Because of the expected predominant effects in the indirect pathway, PDE10A is also hypothesized as a therapeutic target in Huntington’s disease. Increases in cAMP are expected to drive CREB-dependent signaling pathways, known to be dysregulated in Huntington’s disease mouse models (Choi et al., 2009). In line, like rolipram, TP-10 was shown to be neuroprotective in the quinolinic acid model of Huntington’s disease through CREB-mediated neuroprotection (Giampa et al., 2009a). In a follow-up study, PDE10A-1 treatment of R6/2 mice showed significant delays in development of the motor deficits measured in this model accompanied by reduced striatal and cortical cell loss (Giampa et al., 2010). This was accompanied by increased CREB phosphorylation, suggesting that increased cAMP signaling in these brain regions could slow progression of neurodegeneration. Additionally, gene expression studies have implicated PDE10A and cAMP signaling as a therapeutic strategy for Huntington’s disease (Hebb et al., 2004). Chronic treatment of wild-type mice with TP-10 resulted in an increase in gene expression of members of the ERK and PKA signaling pathways as well as an increase in ERK and MSK phosphorylation (Roze et al., 2008; Kleiman et al., 2011; Martin et al., 2011). Both these effects have proven to be neuroprotective in models of Huntington’s disease. Hypothetically, in Parkinson’s disease, PDE10A-Is could be used in the same way to treat dopamine agonist- or levodopa-induced dyskinesias. Chronic treatment with both classes of drugs leads to improvement in symptoms but causes unwanted side effects. These unwanted symptoms are thought to be due to D1 receptor functional supersensitivity, abnormal cAMP signaling, and enhanced ERK signaling (Bezard et al., 2001; Aubert et al., 2005; Santini et al., 2007). Cyclic nucleotide levels were found to be decreased in the brains of rats treated with a combination of levodopa and 6-OHDA (Giorgi et al., 2008). Consistent with this finding, treatment of levodopa-induced dyskinesias with TP-10 reduced the severity of dyskinesias observed in 6-OHDA rats. In this way, PDE10A-Is rescue decreases in cyclic nucleotide levels and prolong the use of levodopa (Wilson and Brandon, 2015).

Preclinical antipsychotic effects of PDE10A-Is may have initiated fronto-striatal disorder-related research, though lack of clinical efficacy and possible extrapyramidal side effects are hampering PDE10A-Is in reaching the market as antipsychotic treatment. An example of the latter is provided by the failure of the Phase II clinical trial of the Pfizer PDE10A-1 MP-10 (or PF-02545920). MP-10 showed no efficacy and produced motor side effects. Despite the serious challenges, there remains interest in PDE10A-Is as an antipsychotic treatment. For instance, Takeda is currently recruiting participants for a clinical Phase II study to evaluate the efficacy, safety, and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia. Efficacy was explained as determining whether cognitive impairment associated with schizophrenia would be attenuated (ClinicalTrials.gov Identifier: NCT02477202). Also, a Phase I study by Hoffmann-La Roche has just been completed in which the safety, tolerability, and pharmacokinetics of RO5459656 in patients with schizophrenia on risperidone was tested (no results have been posted; ClinicalTrials.gov Identifier: NCT02019329). Of note, in 2012 Amon started and terminated a Phase I study to assess the safety and tolerability of their PDE10-A-1 AMG 579 following a single oral dose administration in healthy subjects and patients with schizophrenia or stable schizoaffective disorder (ClinicalTrials.gov Identifier: NCT01568203).

A recent study found no difference in PDE10A mRNA expression between schizophrenia patients and comparison subjects in any of the brain regions studied (thalamus, caudate, putamen, nucleus accumbens, globus pallidus, and substantia nigra). This is the first in vivo assessment of PDE10A expression in patients with schizophrenia. However, this should not be interpreted as a case against developing PDE10A drugs in schizophrenia. The study of intracellular signaling pathways makes a persuasive case for how PDE10A-Is could influence the overall signaling in a therapeutic direction, regardless of whether there is an intrinsic change in PDE10A in schizophrenia (Marques et al., 2016).

Pharmaceutical companies have also started to redesignate their PDE10A-Is to Huntington’s disease. A Phase II proof-of-concept trial is now being initiated in which Pfizer’s PDE10A-1 MP-10 will be tested for safety and efficacy in subjects with Huntington’s disease (ClinicalTrials.gov Identifier: NCT02197130). Omeros initiated a Phase II clinical trial in Huntington’s disease patients with OMS824 after an earlier Phase II trial in schizophrenia patients (no results disclosed; ClinicalTrials.gov Identifier: NCT01952132). The Huntington’s disease trial is a sequential-cohort dose escalation study that evaluates the safety and tolerability of OMS824 over 4 weeks (ClinicalTrials.gov Identifier: NCT02074410). In parallel with the clinical OMS824 trial, Omeros is conducting preclinical rat studies to support clinical trials of longer duration. However, based on that data, there might be a safety issue and based on follow-up communications with the FDA, Omeros has suspended the ongoing Huntington’s disease trial. The FDA has requested that Omeros further evaluates the preclinical data in order to characterize the compound more fully prior to reintititng the clinical trial (Omeros, 2014). Additional support for the
use of PDE10A-Is in Huntington’s disease comes from a recent study that shows that PDE10A levels are lowered early before symptom onset in Huntington’s disease (Niccolini et al., 2015b). Whether this is cause or consequence remains to be determined; however, it most likely resembles a consequence of the degeneration of striatal cells and therefore the PDE10A enzymes within. These results were recently confirmed by a study with the radioligand [18F] MNI-659A (Russell et al., 2016). A comparable large-scale Phase 0 study is currently recruiting new participants. The aim of this study is to measure the availability of the PDE10A enzyme in Huntington’s disease gene expansion carriers using the recently developed radioligand [18F] MNI-659. The study will be cross-sectional, examining Huntington’s disease gene expansion carriers at different stages of the disease (premanifest, stage 1, and stage 2) compared with healthy controls (ClinicalTrials.gov Identifier: NCT02061722).

Of note, Niccolini et al. (2015a) also demonstrated striatal and pallidal loss of PDE10A expression in Parkinson’s disease patients, which is associated with Parkinson’s disease duration and severity of motor symptoms and complications. These results suggest that dopaminergic nigrostriatal degeneration affects the expression of PDE10A in striatum and pallidum. Hypothesizing, it most likely resembles a compensatory mechanism. Less dopaminergic input from the SNC equals less cAMP activation in striatal and pallidal areas decreasing the required levels of PDE10A. In another, more implausible scenario, the decrease is causative. The decrease in PDE10A levels reflects the overall expression of PDE10A in these brain areas not specified for the direct and indirect pathway. Because of the stronger expression of PDE10A in the indirect pathway compared with the direct pathway, PDE10A degeneration will affect the indirect pathway more strongly. Subsequently, reduced PDE10A expression results in enhanced activation of the indirect pathway, resulting in increased inhibition of movement. In both Parkinson’s disease and Huntington’s disease, altered PDE10A expression results in enhanced activation of the indirect pathway. However, the decrease in PDE10A levels is not only due to dopaminergic nigrostriatal degeneration but also to other factors such as compensatory/consequential instead of causative.

In hyperkinetic movement disorders like Huntington’s disease, PDE10A may thus be a promising target for pharmacological agents (PDE10A-Is enhance the little cAMP signaling that is left in the indirect pathway).

Conclusion

Clinical trials investigating the effects of PDE-Is in neuropsychiatric disorders are overall very sparse, and the wealth of positive preclinical data could not yet be translated into clinical efficacy. As a result, no definitive conclusions can be drawn merely based on clinical trial outcomes. Therefore, the current review provides a discussion of the role of PDEs in dopaminergic frontal and striatal signaling and the potential of their associated inhibitors in specific disorders of the fronto-striatal circuits. Subsequently, an overview is provided of the current clinical status.

The fronto-striatal circuits compose the neurobiological basis for several neuropsychiatric disorders, including Parkinson’s disease, Huntington’s disease, ADHD, Tourette’s syndrome, schizophrenia, and obsessive-compulsive disorder. The fronto-striatal circuits constitute a plurality of parallel segregated circuits, which can be clustered together in motor circuits, associative/cognitive circuits, and limbic circuits (Krack et al., 2010). Together, dysfunctions in these circuits produce the wide range of symptoms observed in related neuropsychiatric disorders.

Intracellularly, direct and indirect pathway signaling in the striatum is largely mediated through the cAMP/PKA cascade (Nishi et al., 2008, 2011; Nishi and Snyder, 2010). Cyclic nucleotide cascades are involved in synaptic transmission, neuron excitability, neuroplasticity, and neuroprotection in all types of fronto-striatal circuits (Figure 1). Additionally, all fronto-striatal circuits are modulated by dopamine. Next to the effects of cAMP/PKA pathways on glutamatergic and GABAergic signaling in the fronto-striatal circuits, these cyclic nucleotide pathways also play a major role in the dopaminergic modulation of the circuits. The intracellular effect of dopamine is mediated through dopamine receptor-regulated activation of cAMP/PKA and subsequent DARPP-32 and CREB phosphorylation in both striatal and frontal neurons.

In the last decades, PDEs have therefore received increased attention for their possible role in disorders involving the fronto-striatal circuits. Based on overall expression patterns in frontal and striatal dopaminergic terminals, indirect pathway neurons, and direct pathway neurons, PDE1B, PDE2A, PDE4, PDE7B, PDE9A, and PDE10A seem to be the most interesting targets (Lakics et al., 2010), although most attention and research have thus far been devoted to the potential of PDE1B, PDE4, and PDE10A due to their role in dopaminergic signaling. The main site of action and expression of PDE1B, PDE4, and PDE10A as discussed in this clinical review is inferred from biochemical analyses of striatal cAMP/PKA effectors, behavioral phenotypes of knockout mice, and the observation of effects of subtype-specific PDE-Is on dopamine-related behavior. The different PDE subtypes, and more specifically their splice variants, can be related to different disorders due to their differential expression in one or more of the frontal and striatal pathways or dopaminergic terminals inducing stimulation of dopamine synthesis, the inhibition of D2 receptor signaling or the stimulation of D1 receptor signaling. The different PDE isoforms contain a multiplicity of structural and biochemical properties and are located in specific subcellular compartments, with specific transcriptional and posttranscriptional regulation (Keravis and Lugnier, 2012). Therefore, expression of a PDE subtype in a brain area does not make it an interesting target per se. Their particular involvement in dopaminergic modulation of fronto-striatal signaling is what makes them an interesting target for related disorders. Preferably, the targeted cyclic nucleotide signaling cascade is involved in the pathology of the disorder or contributes to the reduction of the pathology. However, even if this is not the case, PDE inhibition could still influence the overall signaling in a therapeutic direction. Currently, researchers are just beginning to unravel the precise subcellular localization and the role of functional compartmentalization in physiological and pathological conditions of the fronto-striatal circuits (e.g., PDE10A: Russwurm et al., 2015; Li et al., 2016b; MacMullen et al., 2016). Another important consideration is that, in general, PDE-I research involving fronto-striatal disorders is based on the classical view of basal ganglia direct and indirect pathway functioning. Considerable evidence is accumulating to challenge this classical view (Cui et al., 2013; Calabresi et al., 2014; Keeler et al., 2014).

From a therapeutic perspective, inhibition of PDEs with increased expression appears most promising. This way, cognition and plasticity deficits resulting from impaired cAMP/PKA signaling might be improved by inhibiting specific PDE isoforms. However, PDE inhibition might have negative effects on cognition and plasticity when PDEs are already downregulated and cAMP levels and PKA activity are high. In this scenario, elevated cAMP levels might go over a physiological level and disrupt signaling. Along this line, high doses of rolipram impaired prefrontal cognitive function in aged but not young monkeys, likely due to overstimulation of the already disinhibited cAMP/PKA...
signaling pathway in the aged prefrontal cortex (Ramos et al., 2003; Arnsten et al., 2005). This argues to specifically target PDEs that are overexpressed (Table 2).

In addition to the backbone formed by frontal neurons, MSNs and their dopaminergic modulation, the importance of interneurons in physiological and pathologic striato-frontal functioning is becoming increasingly apparent. Several types of interneurons can be found in the striatum, like cholinergic and different GABAergic interneurons (Gerfen and Surmeier, 2011). In particular, nitric oxide synthase containing GABAergic interneurons we would like to highlight. These nitric oxide-producing interneurons play an important role in fronto-striatal functioning (West and Tseng, 2011). Nitric oxide diffuses from these interneurons into dendrites of MSNs that contain high levels of guanylate cyclase, which, when activated, lead to the synthesis of cGMP (Figure 1). In the intact striatum, transient elevations in intracellular cGMP primarily act to increase neuronal excitability and to facilitate glutamatergic fronto-striatal transmission (West and Tseng, 2011; Threlfell and West, 2013). Although the main focus in the fronto-striatal system has been on cAMP signaling, several PDEs (also) target cGMP (e.g., PDE1s and PDE10-Is) and may exert their effects (additionally) on the cGMP signaling cascade (Padovan-Neto et al., 2015).

Summarizing, increased understanding of the subcellular localization and unraveling of the signalosome concept of PDEs including its function and dysfunction in the fronto-striatal circuits will contribute to the design of new specific inhibitors and enhance the potential of PDE-Is as therapeutics in fronto-striatal circuits.

Acknowledgments

PRAH is financially supported by the Human Enhancement and Learning (HEaL) initiative of Maastricht University.

Statement of Interest

L.W. is an employee of Intra-Cellular Therapies, which has a financial interest in the PDE1 inhibitor ITI-214. M.A.v.D., A.B., and J.P. have a proprietary interest in the PDE4 inhibitor roflumilast.

References

Alexander GE, Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13:266–271.

Alexander GE, Crutcher MD, DeLong MR (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Prog Brain Res 85:119–146.

Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381.

Arnsten AF (2013) The neurobiology of thought: the ground-breaking discoveries of Patricia Goldman-Rakic 1937–2003. Cereb Cortex 23:2269–2281.

Arnsten AF, Pliszka SR (2011) Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav 99:211–216.

Arnsten AF, Ramos BP, Birnbaum SG, Taylor JR (2005) Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. Trends Mol Med 11:121–128.

Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57:17–26.

Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, Greengard P (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11:932–939.

Baumeister AA, Francis JL (2002) Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 11:265–277.

Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182–217.

Becker A, Grecksch G (2008) Phosphodiesterase inhibitors—are they potential neuroleptic drugs? Behav Brain Res 186:155–160.

Belmaker RH, Ebstein RF, Biederman J, Stern R, Berman M, van Praag HM (1978) The effect of L-dopa and propranolol on

Table 2. Changes in Human Phosphodiesterase mRNA Levels in Several Fronto-Striatal Disorders

|                | Schizophrenia | Parkinson’s Disease | Huntington’s Disease |
|----------------|--------------|---------------------|----------------------|
|                | Cerebellum   | Striatum            | Pallidum             | Striatum           | Pallidum           | Thalamus           |
| PDE1           | + (1C)       | NS                  | NS                   | NS                 | NS                 | NS                 |
| PDE2           | NS           | NS                  | NS                   | NS                 | NS                 | NS                 |
| PDE3           | =            | NS                  | NS                   | NS                 | NS                 | NS                 |
| PDE4           | (4A1, 4A5, 4A8) | NS            | NS                   | NS                 | NS                 | NS                 |
| PDE5           | NS           | NS                  | NS                   | NS                 | NS                 | NS                 |
| PDE6           | NS           | NS                  | NS                   | NS                 | NS                 | NS                 |
| PDE7           | NS           | NS                  | NS                   | NS                 | NS                 | NS                 |
| PDE8           | (8B)         | NS                  | NS                   | NS                 | NS                 | NS                 |
| PDE9           | NS           | NS                  | NS                   | NS                 | NS                 | NS                 |
| PDE10          | (10A)        | (10A)               | (10A)                | (10A)             | (10A)             | (10A)             |
| PDE11          | NS           | NS                  | NS                   | NS                 | NS                 | NS                 |

+, increased; -, decreased; =, no change; NS, not studied; (Fatemi et al., 2008a, 2008b, 2010; Niccolini et al., 2015a, 2015b; Marques et al., 2016; Russell et al., 2016).
human CSF cyclic nucleotides. Psychopharmacology (Berl) 58:307–310.

Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520.

Bezard E, Erotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577–588.

Bruel-Jungerman E, Davis S, Rampon C, Laroche S (2006) Long-term potentiation enhances neurogenesis in the adult dentate gyrus. J Neurosci 26:5888–5893.

Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, Cherghi K, Svenningsson P, Fienberg AA, Greengard P (2000) Dopamine and cAMP-regulated phosphoprotein 32kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J Neurosci 20:8443–8451.

Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M (2014) Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci 17:1022–1030.

Carew TJ, Sutton MA (2001) Molecular stepping stones in memory consolidation. Nat Neurosci 4:769–771.

Casacchia M, Meco G, Castellana F, Bedini L, Cusimano G, Agoli A (1983) Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson’s disease. Pharmacol Res Commun 15:329–334.

Chauhan NB, Siegel GJ, Lee JM (2001) Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson’s disease brain. J Chem Neuroanat 21:277–288.

Chen X, Xu L, Radcliffe P, Sun B, Tank AW (2008) Activation of tyrosine hydroxylase mRNA translation by cAMP in midbrain dopaminergic neurons. Mol Pharmacol 73:1816–1828.

Cherry JA, Davis RL (1999) Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 407:287–301.

Choi YS, Lee B, Cho HY, Reyes IB, Pu XA, Saito TC, Hoyt KR, Obrist K (2009) CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington’s disease. Neurobiol Dis 36:259–268.

Cui G, Jun SB, Jin X, Pham MD, Vogel SS, Lovingim DM, Costa RM (2013) Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 494:238–242.

D’Sa C, Tolbert LM, Conti M, Duman RS (2002) Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem 81:745–757.

DeMarch Z, Giampa C, Patassini S, Borreca A, Marullo F, Laurenti D, Giampa C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco FR (2009a) Phosphodiesterase 10 inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington’s disease. Eur J Neurosci 30:3813–3828.

Ehrman LA, Williams MT, Schaefer TL, Gudelsky GA, Reed TM, Fienberg AA, Greengard P, Vorhees CV (2006) Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav 5:540–551.

Esposito K, Reierston GW, Luo HR, Wu GS, Licinio J, Wong ML (2009) Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 41:177–185.

Fatemi SH, Jao, P, Reutiman TJ, Folsom TD, Laurence JA, Lee S, Fan YT, Paciga SA, Conti M, Menniti FS (2008a) PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res 101:36–49.

Fatemi SH, Reutiman TJ, Folsom TD, Lee S (2008b) Phosphodiesterase-4A expression is reduced in cerebella of patients with bipolar disorder. Psychiatr Genet 18:282–288.

Fatemi SH, Folsom TD, Reutiman TJ, Vazquez C (2010) Phosphodiesterase signaling system is disrupted in the cerebella of subjects with schizophrenia, bipolar disorder, and major depression. Schizophr Res 119:266–267.

Feng L, Wang CY, Jiang H, Oho C, Mizuno K, Dugich-Djordjevic M, Lu B (1999) Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons. Brain Res Mol Brain Res 66:62–70.

Ferre S, Quiroz C, Orru M, Guitart X, Navarro G, Cortes A, Casado V, Canela EJ, Lluis C, Franco R (2011) Adenosine A2A receptors and A2A receptor heteromers as key players in striatal function. Front Neuroanat 5:36.

Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C, Wolf R, Gerlach W, Jaklitsch H, Sastre-y-Hernandez M, et al. (1992) A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 25:69–64.

Fusco FR, Giampa C (2015) Phosphodiesterases as therapeutic targets for Huntington’s disease. Curr Pharm Des 21:365–377.

Gentzel RC, Toolan D, Roberts R, Kondebo M, Hershey J, Reenger J, Uslaner J, Smith SM (2015) The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents. Neuropsychopharmacology.

Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429–1432.

Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34:441–466.

Giampa C, Laurenti D, Anzliotti S, Bernardi G, Menniti FS, Fusco FR (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington’s disease. PLoS One 5:e13417.

Giampa C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco FR (2009b) Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington’s disease. Eur J Neurosci 29:902–910.

Giampa C, Patassini S, Borreca A, Laurenti D, Marullo F, Bernardi G, Menniti FS, Fusco FR (2009a) Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington’s disease. Neurobiol Dis 34:450–456.
Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 27:2803–2820.

Giorgi M, D’Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G, Sancesario G (2008) Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 28:941–950.

Grauer SM, Pullito VL, Navarra RJ, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574–590.

Greengard P (2001) The neurobiology of dopamine signaling. Biosci Rep 21:247–269.

Greengard P, Allen PB, Nairn AC (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23:435–447.

Gresack JE, Seymour PA, Schmidt CJ, Risbrough VB (2014) Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating. Psychopharmacology (Berl) 231:2189–2197.

Guan F, Zhang C, Wei S, Zhang H, Gong X, Feng J, Gao C, Su R, Yang H, Li S (2012) Association of PDE4B polymorphisms and schizophrenia in Northwestern Han Chinese. Hum Genet 131:1047–1056.

Gurney ME, Burgin AB, Magnusson OT, Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol:167–192.

Haber SN, Rauch SL (2010) Neurocircuity: a window into the networks underlying neuropsychiatric disease. Neuropsychopharmacology 35:1–3.

Hannan AJ (2009) Towards a therapy for Huntington’s disease (Commentary on Giampaoli et al.). Eur J Neurosci 29:901.

Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40–68; image 45.

Hedb AL, Robertson HA (2008) PDEs as drug targets for CNS immune disorders. Curr Opin Investig Drugs 9:744–753.

Hebb AL, Robertson HA, Denovan-Wright EM (2004) Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967–981.

Heckman PR, Blokland A, Ramaekers J, Pickarsts J (2015) PDE and cognitive processing: beyond the memory domain. Neurobiol Learn Mem 119:108–122.

Houslay MD (1995) Compartamentalization of cyclic AMP phosphodiesterases, signalling ‘crosstalk’, desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Adv Enzyme Regul 35:303–338.

Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1–18.

Houslay MD, Baillie GS, Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signalling. Circ Res 100:950–966.

Houslay MD, Milligan G (1997) Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 22:217–224.

Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA (2000) Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra. Exp Neurol 166:127–135.

Hulsey P, Hartikka J, Lubbert H (1995a) Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MFP+. J Neural Transm Suppl 46:217–228.

Hulsey P, Hartikka J, Abdel’Al S, Engels P, Buerki HR, Wiederhold KH, Mulier T, Kelly P, Lowe D, Lubbert H (1995b) Inhibitors of type IV phosphodiesterases reduce the toxicity of MFTP in substantia nigra neurons in vivo. Eur J Neurosci 7:2431–2440.

Hung HC, Lee EH (1996) The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MFTP and MFP+ toxicity: role of BDNF gene expression. Brain Res Mol Brain Res 41:14–26.

Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay R (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230–232.

Imanishi T, Sawa A, Ichimaru Y, Miyashiro M, Kato S, Yamamoto T, Ueki S (1997) Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur J Pharmacol 321:273–278.

Impye S, Mark M, Villacres EC, Poser S, Chavkin C, Storm DR (1996) Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 16:973–982.

Intra-Cellular Therapies (2014) Products and technology: PDE inhibitor platform. Available at http://www.intracellulartherapies.com/products-technology/pde-inhibitor-platform.html.

Izquierdo I, Bevilacqua LR, Rossato JI, Bonini JS, Medina JH, Camarota M (2006) Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci 29:496–505.

Jurevicius J, Fischmeister R (1996) cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci U S A 93:295–299.

Keeler JF, Pretsell DO, Robbins TW (2014) Functional implications of dopamine D1 vs. D2 receptors: A ‘prepare and select’ model of the striatal direct vs. indirect pathways. Neuroscience 282C:156–175.

Kehler J, Nielsen J (2011) PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 17:137–150.

Keravis T, Lugnier C (2012) Cyclic nucleotide phosphodiesterase (PDE) isoforms as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165:1288–1305.

Kleinam RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romenegalli A, Miller KS, Willis A, des Etages S, Kuhn M, Schmidt CJ (2011) Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington’s disease. J Pharmacol Exp Ther 336:64–76.

Kotera J, Sasaki T, Kobayashi T, Fujishige K, Yamashita Y, Yomori K (2004) Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization of the dopamine D1 receptor: the DARPP-32/protein phosphatase-1 cascade. Neurosci Bull 165:1288–1305.

Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA (2010) Deep brain stimulation: from neurology to psychiatry? Trends Neurosci 33:474–484.

Kritzer MD, Li J, Dodge-Kafka K, Kapiloff MS (2012) AKAPs: the architectural underpinnings of local cAMP signalling. J Mol Cell Cardiol 52:351–358.

Kumer SC, Vrana KE (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67:443–462.
in vascular smooth muscle cell growth and survival. Circ Res 98:777–784.

Niccolini F, Foltynie T, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Kapur S, Rabiner EA, Gunn RN, Piccini F, Politis M (2015a) Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson’s disease. Brain 138:3003–3015.

Niccolini F, Haider S, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Piccini F, Kapur S, Rabiner EA, Gunn RN, Tabrizi SJ, Politis M (2015b) Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease. Brain 138:3016–3029.

Nishino N, Kitamura N, Hashimoto T, Tanaka C (1993) Transmembrane signalling systems in the brain of patients with Parkinson’s disease. Rev Neurosci 4:213–222.

Nishi A, Snyder GL (2010) Advanced research on dopamine signalling in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography: Comparison with monkey and rat brain. J Chem Neuroanat 20:349–374.

Nishi A, Kuroiwa M, Shuto T (2011) Mechanisms for the modulation of dopamine d1 receptor signaling in striatal neurons. Front Neuroanat 5:43.

Nishi A, Nishino N, Hashimoto T, Tanaka C (1993) Transmembrane signalling systems in the brain of patients with Parkinson’s disease. Rev Neurosci 4:213–222.

Pliszka SR (2005) The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1385–1390.

Porritt MJ, Batchelor PE, Howells DW (2005) Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol 192:226–234.

Prickaerts J (2015) Phosphodiesterase inhibitors. In: Encyclopedia of psychopharmacology (Stoterman I, ed), pp1306–1315. Berlin, Heidelberg: Springer.

Ramos BP, Birnbaum SG, Lindenmeyer I, Newton SS, Duman RS, Arnsten AF (2003) Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron 40:835–845.

Russell DS, Jennings DL, Barret O, Tamagnan GD, Carroll VM, Caille F, Alagille D, Morley TJ, Papin C, Seibyl JP, Marek KL (2016) Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. Neurology 86:748–754.

Russwurm C, Koedling D, Russwurm M (2015) Phosphodiesterase 10A is tethered to a synaptic signaling complex in striatum. J Biol Chem 290:11936–11947.

Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L, Wallace TL (2008) Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. Eur J Neurosci 28:625–632.

Rutten K, Wallace TL, Works M, Prickaerts J, Blokland A, Novak TJ, Santarelli L, Misner DL (2011) Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B-/-) mice. Neuropharmacology 61:138–147.

Sachs NA, Sawa A, Holmes SE, Ross CA, DeLisi LE, Margolis RL (2005) A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. Mol Psychiatry 10:758–764.

Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M (2005) Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1239–1247.

Sakamoto K, Karelina K, Obrietan K (2011) CREB: a multifaceted regulator of neuronal plasticity and protection. J Neurochem 116:1–9.

Sancegrio G, Giorgi M, D’Angelo V, Modica A, Martorana A, Morello M, Bengtson CP, Bernardi G (2004) Down-regulation...
of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci 20:989–1000.

Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuron-speciﬁc phosphodiesterase 10A2. J Neurochem 105:546–556.

Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girauta J, Herve D, Greengard P, Fisone G (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27:6995–7005.

Schmidt CJ, Chapin DS, Cianfroga J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD III, Williams BD, Verhoest PR, Menniti FS (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:581–590.

Schoffelmeer AN, Wardeh G, Mulder AH (1985) Cyclic AMP facilitates the electrically evoked release of radiolabelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 330:74–76.

Scott Bitner R (2012) Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer’s disease therapeutics. Biochem Pharmacol 83:705–714.

Shults CW, Kimber T, Altar CA (1995) BDNF attenuates the effects of intrastriatal injection of 6-hydroxypseudopine. Neuroreport 6:1109–1112.

Sibley DR, Monsma FJ Jr, Shen Y (1993) Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol 35:391–415.

Siuciak JA (2008) The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22:983–993.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ (2006) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386–396.

Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR (2007) Behavioral and neurochemical characterization of mice deﬁcient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology 53:113–124.

Song RS, Massenburg B, Wenderski W, Jayaraman V, Thompson L, Neves SR (2013) ERK regulation of phosphodiesterase 4 enhances dopamine-stimulated AMPA receptor membrane insertion. Proc Natl Acad Sci U S A 110:15437–15442.

Sotty F, Montezino LP, Steiniger-Brach B, Nielsen J (2009) cGMP-cAMP interplay in cardiac myocytes: a local affair with far-reaching consequences for heart function. Biochem Soc Trans 40:11–14.

Strange PG (1998) Pathology and drug action in schizophrenia: insights from molecular biology. Essays Biochem 33:105–116.

Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ (2010) Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropsychopharmacology 35:671–681.

Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI (2005) Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease. Brain Res 1052:119–129.

Surmeier DJ, Carrillo-Reid L, Bargas J (2011) Dopaminergic modulation of striatal neurons, circuits, and assemblies. Neuroscience 198:3–18.

Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228–235.

Suzuki K, Harada A, Suzuki H, Miyamoto M, Kimura H (2016) TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms. Neuropsychopharmacology. Advance online publication. doi: 10.1038/npp.2016.20.

Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P (2004) DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44:269–296.

Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR (2009) Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther 328:785–795.

Threlfell S, West AR (2013) Review: modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition. Basal Ganglia 3:137–146.

Volcic L, Beal MF, Direnfeld LK, Marquis JK, Albert ML (1986) CSF cyclic nucleotides and somatostatin in Parkinson’s disease. Neurology 36:89–92.

Walker FO (2007) Huntington’s disease. Lancet 369:218–228.

Wennglo LP, Snyder G, Li P, Vanover K, Davis R, Fienberg A, Hendricks J, Mates S (2010) Enhancement of cognition in schizophrenia via inhibition of phosphodiesterase-1B and potentiation of dopamine D1 receptor signaling. Schizophrenia Res 117:489.

West AR, Tseng KY (2011) Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new targets for the treatment of Parkinson’s Disease? Front Syst Neurosci 5:55.

Wilson LS, Baille GS, Pritchard LM, Umana B, Terrin A, Zuccolotto D, Mouslay MD, Maurice DH (2011) A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells. J Biol Chem 286:16285–16296.

Wilson LS, Brandon NJ (2015) Emerging biology of PDE10A. Curr Pharm Des 21:378–388.

Wintener G (2006) Cortical microcircuits in schizophrenia—the dopamine hypothesis revisited. Pharmacopsychiatry 39:568–71.

Wintener G, Weinberger DR (2004) Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 27:683–690.

Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morgan DT, Stephenson DT, Strick CA, Williams RD, Menniti FS (2006) Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139:597–607.

Yamashita N, Hayashi A, Baba J, Sawa A (1997a) Rolipram, a phosphodiesterase 4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons. Jpn J Pharmacol 75:155–159.

Yamashita N, Miyashiro M, Baba J, Sawa A (1997b) Rolipram, a selective inhibitor of phosphodiesterase type 4, pronounc-
edly enhanced the forskolin-induced promotion of dopamine biosynthesis in primary cultured rat mesencephalic neurons. Jpn J Pharmacol 75:91–95.

Yang L, Calingasan NY, Lorenzo BJ, Beal MF (2008) Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol 211:311–314.

Zaccolo M, De Giorgi F, Cho CY, Feng L, Knapp T, Negulescu PA, Taylor SS, Tsien RY, Pozzan T (2000) A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat Cell Biol 2:25–29.

Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M (1984) Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17:188–190.

Zhang HT (2010) Phosphodiesterase targets for cognitive dysfunction and schizophrenia—a New York Academy of Sciences Meeting. iDrugs 13:166–168.